High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer

被引:47
|
作者
Lin, Yang [1 ]
Lv, Feng [1 ]
Liu, Fangfang [1 ]
Guo, Xiaojing [1 ]
Fan, Yu [1 ]
Gu, Feng [1 ]
Gu, Jun [2 ,3 ]
Fu, Li [1 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab,Natl Clin Res C, Key Lab Breast Canc Prevent & Therapy,Minst Educ, Tianjin 300060, Peoples R China
[2] SUNY Albany, Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA
[3] SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 11期
基金
中国国家自然科学基金;
关键词
Pyruvate kinase M2; breast cancer chemosensitivity; epirubicin; 5-fluorouracil; DRUG-SENSITIVITY TEST; IN-VITRO; PKM2; CULTURE; CHEMOTHERAPY; RESISTANCE; CELLS; INHIBITION; PROGNOSIS; THERAPY;
D O I
10.7150/jca.12719
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pyruvate kinase M2 (PKM2) is the key enzyme in the Warburg effect, and it was recently reported to be involved in the metabolic pathways of chemotherapeutic drugs. However, the role of PKM2 in breast cancer and its influence in the sensitivity to front-line anticancer drugs remains unclear. Methods: In this study, we examined the correlation between the expression of PKM2 and the sensitivity of primary breast cancer cells to anticancer drugs. PKM2 expression was studied by immunohistochemistry using biopsy samples of 296 patients diagnosed with invasive breast carcinoma, and the collagen gel droplet embedded culture-drug sensitivity tests (CD-DST) was conducted to all the patients to detect in vitro chemosensitivity after surgery. Results: We found high PKM2 expression was significantly associated with in vitro chemosensitivity to epirubicin (EPI) (P=0.019) and 5-fluorouracil (5-Fu) (P=0.009) in breast cancer patients. Then we used a small group of neoadjuvant chemotherapy cases to confirm that the higher PKM2 expression, the better pathological response to therapy was obtained in patients treated with EPI-based or EPI plus 5-Fu chemotherapy regimens. Although univariate and multivariate analysis indicated that high PKM2 was a poor independent predictor of progression free survival (PFS) and overall survival (OS) in breast cancer, patients with PKM2 high expression who received EPI-based or EPI plus 5-Fu chemotherapy were found to have a longer PFS (P=0.003, P=0.013) and OS (P=0.003, P=0.004) than patients treated with non-EPI/5-Fu-based regimens, respectively. Conclusions: Our findings confirmed the poor prognosis of high PKM2 expression in breast cancer patients and revealed the predictive value of high PKM2 in the therapeutic response to EPI and 5-Fu. Moreover, our results provide the guidance of individual treatment for breast cancer patients who are foreboded a poor prognosis by the presence of high PKM2 status.
引用
收藏
页码:1130 / 1139
页数:10
相关论文
共 50 条
  • [1] Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
    Jamieson, David
    Lee, Jo
    Cresti, Nicola
    Jackson, Rosanna
    Griffin, Melanie
    Sludden, Julieanne
    Verrill, Mark
    Boddy, Alan V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 667 - 674
  • [2] Breast Cancer Resistance Protein Expression and 5-Fluorouracil Resistance
    JIAN-HUI YUAN*
    #Toxicology Laboratory
    ?Department of Emergency
    +Department of General Surgery
    Biomedical and Environmental Sciences, 2008, (04) : 290 - 295
  • [3] The Clinicopathological and Prognostic Relevance of Pyruvate Kinase M2 and pAkt Expression in Breast Cancer
    Benesch, Carina
    Schneider, Christine
    Voelker, Hans-Ullrich
    Kapp, Michaela
    Caffier, Hans
    Krockenberger, Mathias
    Dietl, Johannes
    Kammerer, Ulrike
    Schmidt, Melanie
    ANTICANCER RESEARCH, 2010, 30 (05) : 1689 - 1694
  • [4] Breast cancer resistance protein expression and 5-fluorouracil resistance
    Yuan, Jian-Hui
    Cheng, Jin-Quan
    Jiang, Long-Yuan
    Ji, Wei-Dong
    Guo, Liang-Feng
    Liu, Jian-Jun
    Xu, Xing-Yun
    He, Jing-Song
    Wang, Xian-Ming
    Zhuang, Zhi-Xiong
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2008, 21 (04) : 290 - 295
  • [5] 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE (FEC COMBINATION) IN ADVANCED BREAST-CANCER
    ZAMAGNI, C
    MARTONI, A
    ERCOLINO, L
    BARONI, M
    TANNEBERGER, S
    PANNUTI, F
    JOURNAL OF CHEMOTHERAPY, 1991, 3 (02) : 126 - 129
  • [6] Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
    David Jamieson
    Jo Lee
    Nicola Cresti
    Rosanna Jackson
    Melanie Griffin
    Julieanne Sludden
    Mark Verrill
    Alan V. Boddy
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 667 - 674
  • [7] A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer
    Pacchiarotti, Isabella
    Mazzarini, Lorenzo
    Pellegrini, Patrizia
    Venturelli, Viola
    Sani, Gabriele
    Sanchez-Moreno, Jose
    Mancinelli, Iginia
    Tatarelli, Roberto
    Kotzalidis, Giorgio D.
    Girardi, Paolo
    GENERAL HOSPITAL PSYCHIATRY, 2007, 29 (05) : 461 - 463
  • [8] Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy
    Kailajärvi, MEH
    Salminen, EK
    Paija, OMM
    Virtanen, AM
    Leino, AE
    Irjala, KA
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1271 - 1274
  • [9] Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value
    Cui, Rong
    Shi, Xing-Yao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11393 - 11399
  • [10] Quercetin potentiates the chemosensitivity of MCF-7 breast cancer cells to 5-fluorouracil
    Mawalizadeh, Fatemeh
    Mohammadzadeh, Ghorban
    Khedri, Azam
    Rashidi, Mojtaba
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (12) : 7733 - 7742